- Canada
- /
- Life Sciences
- /
- CNSX:TELI
Telescope Innovations Full Year 2024 Earnings: CA$0.025 loss per share (vs CA$0.014 loss in FY 2023)
Telescope Innovations (CSE:TELI) Full Year 2024 Results
Key Financial Results
- Revenue: CA$4.43m (up 57% from FY 2023).
- Net loss: CA$1.32m (loss widened by 84% from FY 2023).
- CA$0.025 loss per share (further deteriorated from CA$0.014 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Telescope Innovations shares are up 4.4% from a week ago.
Risk Analysis
Be aware that Telescope Innovations is showing 3 warning signs in our investment analysis and 1 of those shouldn't be ignored...
Valuation is complex, but we're here to simplify it.
Discover if Telescope Innovations might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:TELI
Telescope Innovations
A chemical technology company, develops manufacturing processes and tools for the pharmaceutical and chemical industry in the United States and Canada.
Excellent balance sheet low.